BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June

Day

• 1
• 2
• 3
• 4
• 5
• 7
• 8

• 

  Obesity

  Biohaven looks to obesity to bounce back from run of clinical and regulatory failures

  After trial flops in spinal muscular atrophy, depression and bipolar disorder—and a costly rare disease drug rejection—Biohaven is undergoing a reset, recasting its former SMA candidate for obesity.

  June 1, 2026

   · 

  5 min read

   · 

  Heather McKenzie
• 

  Pancreatic cancer

  ASCO: Revolution poised to capture RAS space as pancreatic cancer dataset ‘derisks’ approval

  Revolution Medicines and its RAS inhibitor daraxonrasib stole the show at the American Society of Clinical Oncology’s annual meeting this weekend, as Truist Securities predicts a possible third quarter launch for the pancreatic cancer drug.

  June 1, 2026

   · 

  3 min read

   · 

  Brianna Abbott
• 

  Lung cancer

  ASCO: Kelun-Merck ADC shines with differentiated overall survival in first-line lung cancer

  Interim overall survival data on a TROP2 ADC from Merck and Chinese partner Kelun-Biotech provide support for the pharma’s big bet on its potential to help navigate Keytruda’s impending loss of exclusivity.

  June 1, 2026

   · 

  2 min read

   · 

  Nick Paul Taylor
• 

  Metabolic disorders

  Lilly maintains deal streak with $1.2B pact for Hanmi’s GLP-2 candidate

  Expanding in the metabolic space, Eli Lilly has struck a back-loaded licensing deal with South Korea’s Hanmi Pharm for a mid-stage GLP-2 agonist being trialed for short bowel syndrome.

  June 1, 2026

   · 

  2 min read

   · 

  Michael Gibney
• 

  Vaccines

  Moderna partners with CEPI on Ebola vaccine efforts amid outbreak in Africa

  Riding a newfound surge of interest on infectious disease concerns, Moderna is linking up with a global vaccine foundation in hopes of developing a vaccine to slow the new surge in Ebola underway in the Congo and Uganda.

  June 1, 2026

   · 

  2 min read

   · 

  Gabrielle Masson
• 

  Immuno-oncology

  ASCO: Summit reached with China lung data but new climb begins to prove global benefit

  “King Keytruda’s reign continues,” analysts at BMO Capital Markets declared after Chinese data for Summit Therapeutics’ ivonescimab were revealed at the American Society for Clinical Oncology in Chicago.

  June 1, 2026

   · 

  3 min read

   · 

  Annalee Armstrong
• 

  Job Trends

  17 companies expected to create 400+ Massachusetts jobs add under 50

  Seventeen life sciences businesses awarded Massachusetts tax incentives to add and retain 426 combined jobs hit 10% of that target as of Dec. 31. Three companies, including Novartis, had reported layoffs either last year or this year.

  June 1, 2026

   · 

  4 min read

   · 

  Angela Gabriel
• 

  Mergers & acquisitions

  Servier frees Edgewise for cardio mission with $2.65B muscular dystrophy deal

  Edgewise Therapeutics will now focus on a handful of cardiovascular programs including EDG-7500 for hypertrophic cardiomyopathy thanks to the non-dilutive capital from France’s Servier.

  June 1, 2026

   · 

  2 min read

   · 

  Annalee Armstrong
• 

  Manufacturing

  CordenPharma inks AmbioPharm buyout to continue peptide production expansion

  Swiss service provider CordenPharma is acquiring AmbioPharm, gaining facilities such as a plant in South Carolina to provide a fully U.S.-based supply.

  June 1, 2026

   · 

  2 min read

   · 

  Nick Paul Taylor
• 

  Cancer

  ASCO: A battle of bispecifics, Eli Lilly’s big win and more

  Practice-changing data in lung cancer, prostate cancer and more were on display over the weekend at the American Society of Clinical Oncology annual meeting in Chicago. Plus, early readouts on assets that could reshape the cancer landscape.

  June 1, 2026

   · 

  4 min read

   · 

  Brianna Abbott